Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Consensus Rating of “Moderate Buy” from Analysts

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has earned an average rating of “Moderate Buy” from the twenty-seven analysts that are currently covering the stock, Marketbeat Ratings reports. Nine analysts have rated the stock with a hold rating, sixteen have given a buy rating and two have given a strong buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $804.6957.

Several brokerages have recently issued reports on REGN. Morgan Stanley increased their price target on shares of Regeneron Pharmaceuticals from $768.00 to $769.00 and gave the stock an “equal weight” rating in a research report on Monday, February 2nd. Evercore increased their price target on shares of Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the stock an “outperform” rating in a research report on Thursday, January 22nd. JPMorgan Chase & Co. increased their price target on shares of Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the stock an “overweight” rating in a research report on Monday, February 2nd. Oppenheimer reissued an “outperform” rating and set a $865.00 price target (up from $750.00) on shares of Regeneron Pharmaceuticals in a research report on Monday, February 2nd. Finally, Barclays began coverage on shares of Regeneron Pharmaceuticals in a research report on Friday, March 6th. They set an “overweight” rating and a $923.00 price target on the stock.

Regeneron Pharmaceuticals Stock Down 0.4%

Shares of REGN opened at $760.27 on Wednesday. The stock has a market capitalization of $80.38 billion, a PE ratio of 18.29, a P/E/G ratio of 2.02 and a beta of 0.40. Regeneron Pharmaceuticals has a 1 year low of $476.49 and a 1 year high of $821.11. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.39 and a current ratio of 4.13. The company’s 50-day simple moving average is $766.41 and its 200-day simple moving average is $717.18.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.74 by $0.70. The business had revenue of $3.88 billion for the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The business’s quarterly revenue was up 2.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $12.07 earnings per share. Analysts forecast that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 5th. Stockholders of record on Friday, February 20th were given a dividend of $0.94 per share. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend was Friday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 9.05%.

Insider Activity at Regeneron Pharmaceuticals

In related news, Director Huda Y. Zoghbi sold 1,638 shares of the firm’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $781.33, for a total value of $1,279,818.54. Following the sale, the director owned 1,703 shares of the company’s stock, valued at $1,330,604.99. This trade represents a 49.03% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Jason Pitofsky sold 2,036 shares of the firm’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the completion of the sale, the senior vice president directly owned 4,272 shares in the company, valued at approximately $3,325,837.44. This trade represents a 32.28% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 3,774 shares of company stock valued at $2,942,738 over the last 90 days. 7.02% of the stock is owned by corporate insiders.

Institutional Trading of Regeneron Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. WPG Advisers LLC raised its holdings in Regeneron Pharmaceuticals by 312.5% in the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 25 shares in the last quarter. SHP Wealth Management acquired a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $26,000. Salomon & Ludwin LLC acquired a new stake in Regeneron Pharmaceuticals in the third quarter valued at approximately $27,000. Titan Wealth CI Ltd acquired a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $29,000. Finally, Migdal Insurance & Financial Holdings Ltd. acquired a new stake in Regeneron Pharmaceuticals in the second quarter valued at approximately $31,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.